We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Syndax Pharmaceuticals (SNDX) Looks Good: Stock Up 14.3%
Read MoreHide Full Article
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.
None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is SNDX going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Syndax Pharmaceuticals (SNDX) Looks Good: Stock Up 14.3%
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.
None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
SYNDAX PHARMA Price
SYNDAX PHARMA Price | SYNDAX PHARMA Quote
A better-ranked stock in the same industry is Arbutus Biopharma Corporation (ABUS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is SNDX going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>